Previous 10 | Next 10 |
MaxCyte press release (NASDAQ:MXCT): Q4 GAAP EPS of -$0.05 beats by $0.01. Revenue of $10.2M (+18.6% Y/Y) beats by $0.49M. For further details see: MaxCyte GAAP EPS of -$0.05 beats by $0.01, revenue of $10.2M beats by $0.49M
GAITHERSBURG, Md., March 22, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery...
Raymond James has initiated Nkarta (NASDAQ:NKTX) with a buy rating citing the company's allogenic natural killer cell therapy platform for cancer. The firm has a $17 price target (~69% upside based on Thursday's close). Analyst Dane Leone said that he believes the natural killer platform has ...
On Wednesday, life sciences company, MaxCyte (NASDAQ:MXCT) announced the appointment of Dr. Cenk Sumen as its new Chief Scientific Officer. Prior to his appointment, Sumen served Stemson Therapeutics as the Chief Technology Officer, and before that, he has worked for companies including Therm...
GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic disco...
GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic disco...
The following slide deck was published by MaxCyte, Inc. in conjunction with this event. For further details see: MaxCyte (MXCT) Investor Presentation - Slideshow
GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discov...
MaxCyte (NASDAQ:MXCT) signed a strategic platform license (SPL) with Intima Bioscience, a biotech developing genetically engineered cell therapies for solid tumor cancer. Under the terms of the agreement, Intima obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow...
NEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Intima Bioscience, Inc....
News, Short Squeeze, Breakout and More Instantly...
ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioproce...
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bio...
ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc . , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics and inn...